Turkiye Klinikleri Journal of Medical Sciences

.: ORIGINAL RESEARCH
Myrtus communis L. Esansiyel Yağının IL-1β ile Uyarılmış İnsan Bronşiyal Epitel Hücre Hattında Antiinflamatuar Etkilerinin Araştırılması
Investigation of Anti-Inflammatory Effects of Myrtus communis L. Essential Oil on IL-1β Induced Human Bronchial Epithelial Cell Line
Gülay GÜLBOL DURANa,b, Menderes Yusuf TERZİa,b
aHatay Mustafa Kemal Üniversitesi Tıp Fakültesi, Tıbbi Biyoloji ABD, Hatay, TÜRKİYE
bHatay Mustafa Kemal Üniversitesi Sağlık Bilimleri Enstitüsü, Moleküler Biyokimya ve Genetik ABD, Hatay, TÜRKİYE
Turkiye Klinikleri J Med Sci. 2021;41(4):470-7
doi: 10.5336/medsci.2021-81607
Article Language: TR
Full Text
ÖZET
 Amaç: İnflamasyon, bağışıklık sisteminin enfeksiyona, yaralanmaya veya tahrişe ilk biyolojik tepkisi olmakla birlikte kontrol edilemediğinde otoinflamatuar ve nörodejeneratif hastalıklara veya kansere neden olabilir. Myrtus communis L. (MC) Akdeniz bölgesinde yetişen, çokça farmakolojik aktivitesi olan aromatik bir bitkidir. Bu çalışmada, halk arasında sıklıkla kullanılan MC esansiyel yağının antiinflamatuar etkisini araştırmayı amaçladık. Gereç ve Yöntemler: Sağlıklı insan bronşiyal epitel hücre hattı (BEAS-2B) ile hücre kültürü çalışmaları yapıldı. Hücreler; kontrol, interlökin-1 beta (IL-1β) ile inflamatuar hâle getirilen BEAS-2B hücreleri ve MC uygulanan inflamatuar BEAS-2B hücreleri olmak üzere 3 farklı gruba ayrıldı. MC'nin sitotoksik olmayan konsantrasyonları MTT testi ile belirlendi. IL-6, IL-10, uyarılabilir sitrik oksit sentaz [inducible nitric oxide synthase (iNOS)], tümör nekrozis faktör alfa (TNF-α), siklooksigenaz-2 [cyclooxygenase-2 (COX-2)] ve nükleer faktör kappa B (NFκB) genlerinin ekspresyon düzeyleri revers transkriptaz-kantitatif polimeraz zincir reaksiyonu ile saptandı. IL-6, IL-10, iNOS ve TNF-α protein düzeyleri ELISA ile ölçüldü. Bulgular: IL-1β ile uyarılmış inflamatuar hücrelerde artan IL-6, IL-10 ve NFκB mRNA düzeyleri, MC yağı uygulama sonrası anlamlı derecede azalarak bazal seviyelere dönmüştür. IL-6 ve IL-10 protein düzeyleri gen ekspresyon verileriyle uyumlu olarak inflamatuar hâle getirilen grupta artmış olarak saptandı. MC uygulaması inflamatuar hücrelerdeki artan protein düzeylerini kontrol gurubundaki bazal seviyeye döndürdü. Sonuç: Çalışmamızda, MC esansiyel yağının BEAS-2B hücrelerinde proinflamatuar sitokinlerin ekspresyonunu inhibe ederek, antiinflamatuar etkiye sahip olduğunu gösterdik. MC esansiyel yağının güçlü bir antiinflamatuar etkiye sahip potansiyel bir terapötik ajan olarak değerlendirilmesi için farklı konsantrasyonlarla daha fazla araştırma yapılmalıdır.

Anahtar Kelimeler: Myrtus communis L.; antiinflamatuar; BEAS-2B; RT-qPCR; ELISA
ABSTRACT
 Objective: Inflammation is the primary biological response of immune system against infection, injury, and irritation, but when it is not curbed, it can lead to autoimmune and neurodegenerative diseases or cancer. Myrtus communis L. (MC) is an aromatic plant raised in the region of Mediterranean Sea and bearing several pharmacological activities. We aimed in this study to investigate anti-inflammatory effects of MC essential oil that is often utilized by the local population. Material and Methods: Cell culture experiments were conducted with healthy bronchial epithelial lung cell line (BEAS-2B). The cells were grouped in three as follows; non-treated control, interleukin-1 beta (IL-1β) induced inflammatory cells, and MC-treated inflammatory cells. Non-cytotoxic concentrations of MC were determined with MTT assay. The gene expression levels of IL-6, IL-10, inducible nitric oxide synthase (iNOS), tumor necrosis factor alpha (TNF-α), cyclooxygenase-2 (COX-2), and nuclear factor kappa b (NFκB) were analyzed with reverse transcriptase-quantitative polymerase chain reaction. The protein levels of IL-6, IL-10, iNOS, and TNF-α were detected with ELISA. Results: The elevated mRNA levels of IL-6, IL-10, and NFκB in IL-1β-induced inflammatory cells significantly reduced back to the basal levels after MC treatment. In line with the mRNA levels, the protein levels of IL-6 and IL-10 significantly increased in inflammatory cells. MC treatment reversed this increase in protein levels to the baseline as in the control group. Conclusion: We demonstrated in our study the anti-inflammatory effects of MC essential oil on BEAS2B cells by inhibiting the expression of pro-inflammatory cytokines. To be able suggest MC essential oil as a potential therapeutic agent with a strong anti-inflammatory action, further studies testing several concentrations are warranted.

Keywords: Myrtus communis L.; anti-inflammatory; BEAS-2B; RT-qPCR; ELISA
REFERENCES:
  1. Dinarello CA. Anti-inflammatory agents: Present and future. Cell. 2010;140(6):935-50. [Crossref] [PubMed] [PMC] 
  2. Hwang D, Kang MJ, Jo MJ, Seo YB, Park NG, Kim GD. Anti-Inflammatory Activity of β-thymosin Peptide Derived from Pacific Oyster (Crassostrea gigas) on NO and PGE2 Production by Down-Regulating NF-κB in LPS-Induced RAW264.7 Macrophage Cells. Mar Drugs. 2019;17(2):129. [Crossref] [PubMed] [PMC] 
  3. Liu M, Fang G, Yin S, Zhao X, Zhang C, Li J, et al. Caffeic Acid Prevented LPS-Induced Injury of Primary Bovine Mammary Epithelial Cells through Inhibiting NF-κB and MAPK Activation. Mediators Inflamm. 2019;2019:1897820. [Crossref] [PubMed] [PMC] 
  4. Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of inflammation. Methods Mol Biol. 2018;1803:57-79. [Crossref] [PubMed] 
  5. Singh N, Baby D, Rajguru JP, Patil PB, Thakkannavar SS, Pujari VB. Inflammation and cancer. Ann Afr Med. 2019;18(3):121-6. [Crossref]  [PubMed]  [PMC] 
  6. Turner MD, Nedjai B, Hurst T, Pennington DJ. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim Biophys Acta. 2014;1843(11):2563-82. [Crossref] [PubMed] 
  7. Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther. 2017;2:17023-. [Crossref] [PubMed] [PMC] 
  8. Zhu F, Du B, Xu B. Anti-inflammatory effects of phytochemicals from fruits, vegetables, and food legumes: A review. Crit Rev Food Sci Nutr. 2018;58(8):1260-70. [Crossref] [PubMed] 
  9. Lombardo GE, Cirmi S, Musumeci L, Pergolizzi S, Maugeri A, Russo C, et al. Mechanisms underlying the anti-inflammatory activity of bergamot essential oil and its antinociceptive effects. Plants (Basel). 2020;9(6):704. [Crossref] [PubMed] [PMC] 
  10. Lorençoni MF, Figueira MM, Toledo E Silva MV, Pimentel Schmitt EF, Endringer DC, Scherer R, et al. Chemical composition and anti-inflammatory activity of essential oil and ethanolic extract of Campomanesia phaea (O. Berg.) Landrum leaves. J Ethnopharmacol. 2020;252:112562. [Crossref] [PubMed] 
  11. Santos SMD, de Oliveira Junior PC, de Matos Balsalobre N, Kassuya CAL, Cardoso CAL, Pereira ZV, et al. Variation in essential oil components and anti-inflammatory activity of Allophylus edulis leaves collected in central-western Brazil. J Ethnopharmacol. 2021;267:113495. [Crossref] [PubMed] 
  12. Santos SMD, de Oliveira Junior PC, de Matos Balsalobre N, Kassuya CAL, Cardoso CAL, Pereira ZV, et al. Variation in essential oil components and anti-inflammatory activity of Allophylus edulis leaves collected in central-western Brazil. J Ethnopharmacol. 2021;267:113495. [Crossref] [PubMed] 
  13. Ozcan O, Ipekci H, Alev B, Ustundag UV, Ak E, Sen A, et al. Protective effect of Myrtle (Myrtus communis) on burn induced skin injury. Burns. 2019;45(8):1856-63. [Crossref] [PubMed] 
  14. Ulutaş HZ, Duran GG. Antioxidant effects of Myrtus communis L.'s Essential Oils in BEAS-2B cells induced by oxidative stress with hydrogen peroxide. Acta Medica Alanya. 2020;4(1):21-8. [Link] 
  15. Soomro S, Mesaik MA, Shaheen F, Khan N, Halim SA, Ul-Haq Z, et al. Inhibitory Effects of Myrtucommuacetalone 1 (MCA-1) from Myrtus communis on Inflammatory Response in Mouse Macrophages. Molecules. 2019;25(1):13. [Crossref]  [PubMed]  [PMC] 
  16. Barac A, Donadu M, Usai D, Spiric VT, Mazzarello V, Zanetti S, et al. Antifungal activity of Myrtus communis against Malassezia sp. isolated from the skin of patients with pityriasis versicolor. Infection. 2018;46(2):253-7. Erratum in: Infection. 2018. Apr;46(2):253-257. [Crossref]  [PubMed] 
  17. Rahimvand L, Niakan M, Naderi NJ. The antibacterial effect of aquatic and methanolic extract of Myrtus communis on Actinobacillus actinomycetemcomitans, Porphyromonas gingivalis and Prevotella intermedia. Iran J Microbiol. 2018;10(4):254-7. [PubMed]  [PMC] 
  18. Mahboubi M. Effectiveness of Myrtus communis in the treatment of hemorrhoids. J Integr Med. 2017;15(5):351-8. [Crossref] [PubMed] 
  19. Hennia A, Miguel MG, Nemmiche S. Antioxidant Activity of Myrtus communis L. and Myrtus nivellei Batt. & Trab. Extracts: A Brief Review. Medicines (Basel). 2018;5(3):89. [Crossref] [PubMed] [PMC] 
  20. Bilgic N, Duran GG. Chemical Composition of Myrtus communis L. and Proapoptotic Effects on the A549 cell line. Journal of Essential Oil Bearing Plants. 2020;23(6):1283-95. [Crossref] 
  21. Arulselvan P, Fard MT, Tan WS, Gothai S, Fakurazi S, Norhaizan ME, et al. Role of antioxidants and natural products in inflammation. Oxid Med Cell Longev. 2016;2016:5276130. [Crossref] [PubMed] [PMC] 
  22. Jarosz M, Olbert M, Wyszogrodzka G, Młyniec K, Librowski T. Antioxidant and anti-inflammatory effects of zinc. Zinc-dependent NF-κB signaling. Inflammopharmacology. 2017;25(1):11-24. [Crossref] [PubMed] [PMC] 
  23. Liou CJ, Huang WC. Casticin inhibits interleukin-1β-induced ICAM-1 and MUC5AC expression by blocking NF-κB, PI3K-Akt, and MAPK signaling in human lung epithelial cells. Oncotarget. 2017;8(60):101175-188. [Crossref] [PubMed] [PMC] 
  24. Khan YM, Kirkham P, Barnes PJ, Adcock IM. Brd4 is essential for IL-1β-induced inflammation in human airway epithelial cells. PLoS One. 2014; 9(4):e95051. [Crossref] [PubMed] [PMC] 
  25. Ebrahimi F, Mahmoudi J, Torbati M, Karimi P, Valizadeh H. Hemostatic activity of aqueous extract of Myrtus communis L. leaf in topical formulation: In vivo and in vitro evaluations. J Ethnopharmacol. 2020;249:112398. [Crossref]  [PubMed] 
  26. Jabri MA, Hajaji S, Rtibi K, Sebai H. Role of Anti-Inflammatory, Reactive Oxygen Species Scavenging Activity and Nematicidal Properties of Myrtle Berry Seeds on Helminthiasis Treatment. J Med Food. 2021;24(4):377-84. [Crossref] [PubMed] 
  27. Ozbeyli D, Sen A, Cilingir Kaya OT, Ertas B, Aydemir S, Ozkan N, et al. Myrtus communis leaf extract protects against cerulein-induced acute pancreatitis in rats. J Food Biochem. 2020;44(2): e13130. [Crossref] [PubMed] 
  28. Cheng Z, Li L. Ginsenoside Rg3 ameliorates lipopolysaccharide-induced acute lung injury in mice through inactivating the nuclear factor-κB (NF-κB) signaling pathway. Int Immunopharmacol. 2016;34:53-9. [Crossref] [PubMed] 
  29. Lee IS, Uh I, Kim KS, Kim KH, Park J, Kim Y, et al. Anti-Inflammatory Effects of Ginsenoside Rg3 via NF-κB Pathway in A549 Cells and Human Asthmatic Lung Tissue. J Immunol Res. 2016; 2016:7521601. [Crossref] [PubMed] [PMC] 
  30. Kutlu Z, Gulaboglu M, Halıcı Z, Cınar İ, Dıyarbakır B. Biochemical research of the effects of essential oil obtained from the fruit of Myrtus communis L. on cell damage associated with lipopolysaccharide-ınduced endotoxemia in a human umbilical cord vein endothelial cells. Biochem Genet. 2021;59(1):315-34. [Crossref] [PubMed] 
  31. Maxia A, Frau MA, Falconieri D, Karchuli MS, Kasture S. Essential oil of Myrtus communis inhibits inflammation in rats by reducing serum IL-6 and TNF-alpha. Nat Prod Commun. 2011;6(10):1545-8. [Crossref] [PubMed] 
  32. Mitchell S, Vargas J, Hoffmann A. Signaling via the NFκB system. Wiley Interdiscip Rev Syst Biol Med. 2016;8(3):227-41. [Crossref] [PubMed] [PMC] 
  33. Duran GG, Küçük MU, Algül Ö, Terzi MY. Investigation of new benzimidazole derivative compounds' effects on A549 cell line. Brazilian Archives of Biology and Technology. 2020;63. [Crossref] 
  34. Lee M, Wang C, Jin SW, Labrecque MP, Beischlag TV, Brockman MA, et al. Expression of human inducible nitric oxide synthase in response to cytokines is regulated by hypoxia-inducible factor-1. Free Radic Biol Med. 2019;130:278-87. [Crossref] [PubMed] 

.: Up To Date

Login

 Forgot your password?

 New Registration  

Contact

Ortadoğu Reklam Tanıtım Yayıncılık Turizm Eğitim İnşaat Sanayi ve Ticaret A.Ş.

.: Address

Turkocagi Caddesi No:30 06520 Balgat / ANKARA
Phone: +90 312 286 56 56
Fax: +90 312 220 04 70
E-mail: info@turkiyeklinikleri.com

.: Manuscript Editing Department

Phone: +90 312 286 56 56/ 2
E-mail: yaziisleri@turkiyeklinikleri.com

.: English Language Redaction

Phone: +90 312 286 56 56/ 145
E-mail: tkyayindestek@turkiyeklinikleri.com

.: Marketing Sales-Project Department

Phone: +90 312 286 56 56/ 142
E-mail: reklam@turkiyeklinikleri.com

.: Subscription and Public Relations Department

Phone: +90 312 286 56 56/ 118
E-mail: abone@turkiyeklinikleri.com

.: Customer Services

Phone: +90 312 286 56 56/ 118
E-mail: satisdestek@turkiyeklinikleri.com

1. TERMS OF USE

1.1. To use the web pages with http://www.turkiyeklinikleri.com domain name or the websites reached through the sub domain names attached to the domain name (They will be collectively referred as "SITE"), please read the conditions below. If you do not accept these terms, please cease to use the "SITE." "SITE" owner reserves the right to change the information on the website, forms, contents, the "SITE," "SITE" terms of use anytime they want.

1.2. The owner of the "SITE" is Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. (From now on it is going to be referred as "Turkiye Klinikleri", shortly) and it resides at Turkocagi cad. No:30, 06520 Balgat Ankara. The services in the "SITE" are provided by "Turkiye Klinikleri."

1.3. Anyone accessing the "SITE" with or without a fee whether they are a natural person or a legal identity is considered to agree these terms of use. In this contract hereby, "Turkiye Klinikleri" may change the stated terms anytime. These changes will be published in the "SITE" periodically and they will be valid when they are published. Any natural person or legal identity benefiting from and reaching to the "SITE" are considered to be agreed to any change on hereby contract terms done by "Turkiye Klinikleri."

1.4. The "Terms of Use" hereby is published in the website with the last change on March 30th 2014 and the "SITE" is activated by enabling the access to everyone. The "Terms of Use" hereby is also a part of the any "USER Contract" was and/or will be done with the users using "Turkiye Klinikleri" services with or without a fee an inseparable.

2. DEFINITIONS

2.1. "SITE": A website offering different kind of services and context with a certain frame determined by "Turkiye Klinikleri" and it is accessible on-line on http://www.turkiyeklinikleri.com domain name and/or subdomains connected to the domain name.

2.2. USER: A natural person or a legal identity accessing to the "SITE" through online settings.

2.3. LINK: A link enabling to access to another website through the "SITE", the files, the context or through another website to the "SITE", the files and the context.

2.4. CONTEXT: Any visual, literary and auditory images published in the "Turkiye Klinikleri", "SITE" and/or any website or any accessible information, file, picture, number/figures, price, etc.

2.5. "USER CONTRACT": An electronically signed contract between a natural or a legal identity benefiting from special services "Turkiye Klinikleri" will provide and "Turkiye Klinikleri".

3. SCOPE OF THE SERVICES

3.1. "Turkiye Klinikleri" is completely free to determine the scope and quality of the services via the "SITE".

3.2. To benefit the services of "Turkiye Klinikleri" "SITE", the "USER" must deliver the features that will be specified by "Turkiye Klinikleri". "Turkiye Klinikleri" may change this necessity any time single-sided.

3.3. Not for a limited number, the services "Turkiye Klinikleri" will provide through the "SITE" for a certain price or for free are;

- Providing scientific articles, books and informative publications for health industry.

- Providing structural, statistical and editorial support to article preparation stage for scientific journals.

4. GENERAL PROVISIONS

4.1. "Turkiye Klinikleri" is completely free to determine which of the services and contents provided in the "SITE" will be charged.

4.2. People benefiting from the services provided by "Turkiye Klinikleri" and using the website can use the "SITE" only according to the law and only for personal reasons. Users have the criminal and civil liability for every process and action they take in the "SITE". Every USER agrees, declares and undertakes that they will not proceed by any function or action infringement of rights of "Turkiye Klinikleri"s and/or other third parties', they are the exclusive right holder on usage, processing, storage, made public and revealing any written, visual or auditory information reported to Turkiye Klinikleri" and/or "SITE" to the third parties. "USER" agrees and undertakes that s/he will not duplicate, copy, distribute, process, the pictures, text, visual and auditory images, video clips, files, databases, catalogs and lists within the "SITE", s/he will not be using these actions or with other ways to compete with "Turkiye Klinikleri", directly or indirectly.

4.3. The services provided and the context published within the "SITE" by third parties is not under the responsibility of "Turkiye Klinikleri", institutions collaborated with "Turkiye Klinikleri", "Turkiye Klinikleri" employee and directors, "Turkiye Klinikleri" authorized salespeople. Commitment to accuracy and legality of the published information, context, visual and auditory images provided by any third party are under the full responsibility of the third party. "Turkiye Klinikleri" does not promise and guarantee the safety, accuracy and legality of the services and context provided by a third party.

4.4. "USER"s cannot act against "Turkiye Klinikleri", other "USER"s and third parties by using the "SITE". "Turkiye Klinikleri" has no direct and/or indirect responsibility for any damage a third party suffered or will suffer regarding "USER"s actions on the "SITE" against the rules of the hereby "Terms of Use" and the law.

4.5. "USER"s accept and undertake that the information and context they provided to the "SITE" are accurate and legal. "Turkiye Klinikleri" is not liable and responsible for promising and guaranteeing the verification of the information and context transmitted to "Turkiye Klinikleri" by the "USER"s, or uploaded, changed and provided through the "SITE" by them and whether these information are safe, accurate and legal.

4.6. "USER"s agree and undertake that they will not perform any action leading to unfair competition, weakening the personal and commercial credit of "Turkiye Klinikleri" and a third party,  encroaching and attacking on personal rights within the "SITE" in accordance with the Turkish Commercial Code Law.

4.7. "Turkiye Klinikleri" reserves the right to change the services and the context within the "SITE"  anytime. "Turkiye Klinikleri" may use this right without any notification and timelessly. "USER"s have to make the changes and/or corrections "Turkiye Klinikleri" required immediately. Any changes and/or corrections that are required by "Turkiye Klinikleri", may be made by "Turkiye Klinikleri" when needed. Any harm, criminal and civil liability resulted or will result from changes and/or corrections required by "Turkiye Klinikleri" and were not made on time by the "USER"s belongs completely to the users.

4.8. "Turkiye Klinikleri" may give links through the "SITE" to other websites and/or "CONTEXT"s and/or folders that are outside of their control and owned and run by third parties. These links are provided for ease of reference only and do not hold qualification for support the respective web SITE or the admin or declaration or guarantee for the information inside. "Turkiye Klinikleri" does not hold any responsibility over the web-sites connected through the links on the "SITE", folders and context, the services or products on the websites provided through these links or their context.

4.9. "Turkiye Klinikleri" may use the information provided to them by the "USERS" through the "SITE" in line with the terms of the "PRIVACY POLICY" and "USER CONTRACT". It may process the information or classify and save them on a database. "Turkiye Klinikleri" may also use the USER's or visitor's identity, address, e-mail address, phone number, IP number, which sections of the "SITE" they visited, domain type, browser type, date and time information to provide statistical evaluation and customized services.

5. PROPRIETARY RIGHTS

5.1. The information accessed through this "SITE" or provided by the users legally and all the elements (including but not limited to design, text, image, html code and other codes) of the "SITE" (all of them will be called as studies tied to "Turkiye Klinikleri"s copyrights) belongs to "Turkiye Klinikleri". Users do not have the right to resell, process, share, distribute, display or give someone permission to access or to use the "Turkiye Klinikleri" services, "Turkiye Klinikleri" information and the products under copyright protection by "Turkiye Klinikleri". Within hereby "Terms of Use" unless explicitly permitted by "Turkiye Klinikleri" nobody can reproduce, process, distribute or produce or prepare any study from those under "Turkiye Klinikleri" copyright protection.

5.2. Within hereby "Terms of Use", "Turkiye Klinikleri" reserves the rights for "Turkiye Klinikleri" services, "Turkiye Klinikleri" information, the products associated with "Turkiye Klinikleri" copyrights, "Turkiye Klinikleri" trademarks, "Turkiye Klinikleri" trade looks or its all rights for other entity and information it has through this website unless it is explicitly authorized by "Turkiye Klinikleri".

6. CHANGES IN THE TERMS OF USE

"Turkiye Klinikleri" in its sole discretion may change the hereby "Terms of Use" anytime announcing within the "SITE". The changed terms of the hereby "Terms of Use" will become valid when they are announced. Hereby "Terms of Use" cannot be changed by unilateral declarations of users.

7. FORCE MAJEURE

"Turkiye Klinikleri" is not responsible for executing late or never of this hereby "Terms of Use", privacy policy and "USER Contract" in any situation legally taken into account as force majeure. Being late or failure of performance or non-defaulting of this and similar cases like this will not be the case from the viewpoint of "Turkiye Klinikleri", and "Turkiye Klinikleri" will not have any damage liability for these situations. "Force majeure" term will be regarded as outside of the concerned party's reasonable control and any situation that "Turkiye Klinikleri" cannot prevent even though it shows due diligence. Also, force majeure situations include but not limited to natural disasters, rebellion, war, strike, communication problems, infrastructure and internet failure, power cut and bad weather conditions.

8. LAW AND AUTHORISATION TO FOLLOW

Turkish Law will be applied in practicing, interpreting the hereby "Terms of Use" and managing the emerging legal relationships within this "Terms of Use" in case of finding element of foreignness, except for the rules of Turkish conflict of laws. Ankara Courts and Enforcement Offices are entitled in any controversy happened or may happen due to hereby contract.

9. CLOSING AND AGREEMENT

Hereby "Terms of Use" come into force when announced in the "SITE" by "Turkiye Klinikleri". The users are regarded to agree to hereby contract terms by using the "SITE". "Turkiye Klinikleri" may change the contract terms and the changes will be come into force by specifying the version number and the date of change on time it is published in the "SITE".

 

30.03.2014

Privacy Policy

We recommend you to read the terms of use below before you visit our website. In case you agree these terms, following our rules will be to your favor. Please read our Terms of Use thoroughly.

www.turkiyeklinikleri.com website belongs to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. and is designed in order to inform physicians in the field of health

www.turkiyeklinikleri.com cannot reach to user’s identity, address, service providers or other information. The users may send this information to the website through forms if they would like to. However, www.turkiyeklinikleri.com may collect your hardware and software information. The information consists of your IP address, browser type, operating system, domain name, access time, and related websites. www.turkiyeklinikleri.com cannot sell the provided user information (your name, e-mail address, home and work address, phone number) to the third parties, publish it publicly, or keep it in the website. Gathered information has a directing feature to be a source for the website’s visitor profile, reporting and promotion of the services.

www.turkiyeklinikleri.com uses the taken information:

-To enhance, improve and maintain the quality of the website

-To generate visitor’s profile and statistical data

-To determine the tendency of the visitors on using our website

-To send print publications/correspondences

-To send press releases or notifications through e-mail

-To generate a list for an event or competition

By using www.turkiyeklinikleri.com you are considered to agree that;

-Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. cannot be hold responsible for any user’s illegal and immoral behavior,

-Terms of use may change from time to time,

-It is not responsible for other websites’ contents it cannot control or the harms they may cause although it uses the connection they provided.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. may block the website to users in the following events:

-Information with wrong, incomplete, deceiving or immoral expressions is recorded to the website,

-Proclamation, advertisement, announcement, libelous expressions are used against natural person or legal identity,

-During various attacks to the website,

-Disruption of the website because of a virus.

Written, visual and audible materials of the website, including the code and the software are under protection by legal legislation.

Without the written consent of Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. the information on the website cannot be downloaded, changed, reproduced, copied, republished, posted or distributed.

All rights of the software and the design of the website belong to Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc.

Ortadoğu Advertisement Presentation Publishing Tourism Education Architecture Industry and Trade Inc. will be pleased to hear your comments about our terms of use. Please share the subjects you think may enrich our website or if there is any problem regarding our website.

info@turkiyeklinikleri.com